BACK FROM INTERNATIONAL BREAST CONGRESS

1. 1.Apolo AB, Atiq S, Kydd AR, Chelluri R, Millan B, Gurram S, Chandran E, Simon N. Top advances of the year: Bladder cancer. Cancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020. PMID: 40782344. 2025
   Articolo scientificoCancer. 2025 Aug 15;131(16):e70020. doi: 10.1002/cncr.70020. PMID: 40782344Leggi il paperCerca versione gratuita
2. 2.Rutkowski P, Mandala M. Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment. Eur J Surg Oncol. 2024 Mar;50(3):107969. doi: 10.1016/j.ejso.2024.107969. Epub 2024 Feb 2. PMID: 38342039. 2024
   Articolo scientificoEur J Surg Oncol. 2024 Mar;50(3):107969. doi: 10.1016/j.ejso.2024.107969. Epub 2024 Feb 2. PMID: 38342039Leggi il PDF gratuito
3. 3.Liu S, Jiang A, Tang F, Duan M, Li B. Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. Mol Cancer. 2025 May 24;24(1):150. doi: 10.1186/s12943-025-02323-9. PMID: 40413503. 2025
   Articolo scientificoMol Cancer. 2025 May 24;24(1):150. doi: 10.1186/s12943-025-02323-9. PMID: 40413503Leggi il PDF gratuito
4. 4.Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaque S, Cortés J. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Erratum in: Lancet. 2023 Feb 18;401(10376):556. doi: 10.1016/S0140-6736(22)00045-9. PMID: 36495879. 2023
   Articolo scientificoLancet. 2023 Jan 14;401(10371):105-117. doi: 10.1016/S0140-6736(22)02420-5. Epub 2022 Dec 7. Erratum in: Lancet. 2023 Feb 18;401(10376):556. doi: 10.1016/S0140-6736(22)00045-9. PMID: 36495879Leggi il PDF gratuito
5. 5.Khoury T, Gandhi S, Tozbikian G, Fadare O, Syed S, To B, Quiroga D, Yao S, Attwood K, Yu H, Fang Y. Clinicopathological Evaluation of Triple Negative Breast Cancer Treated with keynote-522 regimen. Oncologist. 2025 Jul 24:oyaf231. doi: 10.1093/oncolo/oyaf231. Epub ahead of print. PMID: 40704692. 2025
   Articolo scientificoOncologist. 2025 Jul 24:oyaf231. doi: 10.1093/oncolo/oyaf231. Epub ahead of print. PMID: 40704692Leggi il PDF gratuito

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).